Journal article
Hypertension, white-coat hypertension and masked hypertension in Australia: Findings from the Australian Diabetes, Obesity, and Lifestyle Study 3
GA Head, JE Shaw, DW Dunstan, N Owen, DJ Magliano, S Chadban, P Zimmet
Journal of Hypertension | LIPPINCOTT WILLIAMS & WILKINS | Published : 2019
Abstract
Background and method:The Australian Diabetes, Obesity, and Lifestyle Study is a national, population-based examination of ∼11 000 adults with a third follow-up phase at 12 years. The aim was to use ambulatory blood pressure monitoring (ABPM) in a subsample (n = 508) of the main Australian Diabetes third follow-up cohort to determine the proportion with established, masked or white-coat hypertension in city and regional centers and the effectiveness of diagnosis and treatment.Results:Mean age was 58.9 years, BMI was 27.6 kg/m2 with 53% women. The mean clinic BP was 127/73 mmHg and mean 24-h BP was 121/73 mmHg. Using regression analysis estimations, the predicted ABPM daytime equivalent for t..
View full abstractGrants
Funding Acknowledgements
For funding or logistical support for AusDiab we are grateful to: National Health and Medical Research Council (NHMRC grants 233200 and 1007544), Australian Government Department of Health and Ageing, Abbott Australasia Pty Ltd, Alphapharm Pty Ltd, Amgen Australia, AstraZeneca, Bristol-Myers Squibb, City Health Centre-Diabetes Service -Canberra, Department of Health and Community Services Northern Territory, Department of Health and Human Services -Tasmania, Department of Health - New South Wales, Department of Health -Western Australia, Department of Health -South Australia, Department of Human Services -Victoria, Diabetes Australia, Diabetes Australia Northern Territory, Eli Lilly Australia, Estate of the Late Edward Wilson, GlaxoSmithKline, Jack Brockhoff Foundation, Janssen-Cilag, Kidney Health Australia, Marian & FH Flack Trust, Menzies Research Institute, Merck Sharp & Dohme, Novartis Pharmaceuticals, Novo Nordisk Pharmaceuticals, Pfizer Pty Ltd, Pratt Foundation, Queensland Health, Roche Diagnostics Australia, Royal Prince Alfred Hospital, Sydney, Sanofi Aventis, sanofi-synthelabo, and the Victorian Government's OIS Program.The study was supported by National Health and Medical Research Council grants and in part by the Victorian Government's OIS Program. G.A.H., J.E.S., D.W.D., N.O. and D.J.M. are supported by NHMRC Research Fellowships. No part of this study has been previously published.